Meeting
2021 ASCO Annual Meeting
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases: The PARLIM trial (AIO KRK 0314).
Authors
Dominik Paul Modest
Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
Dominik Paul Modest , Meinolf Karthaus , Stefan Kasper , Nicolas Moosmann , Verena Keitel , Alexander Kiani , Ludwig Fischer von Weikersthal , Jens Uhlig , Lutz Jacobasch , Martin Fuchs , Florian Kaiser , Christian A. Lerchenmuller , Christian Junghanss , Swantje Held , Kathrin Heinrich , Andreas Jung , Arndt Stahler , Sebastian Stintzing , Volker Heinemann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT01384994
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3553)
DOI
10.1200/JCO.2021.39.15_suppl.3553
Abstract #
3553
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Outcomes of oxaliplatin-based (Ox) chemotherapy (CT) on R0 resection of colonic liver metastases (CLM).
First Author: Nicholas Adam Bosma
Poster
2018 Gastrointestinal Cancers Symposium
SAPPHIRE: A randomized phase II study of mFOLFOX6 + panitumumab versus 5-FU/LV + panitumumab after 6 cycles of frontline mFOLFOX6 + panitumumab in patients with colorectal cancer.
First Author: Masato Nakamura
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TnT) with FOLFOX followed by short course radiation in locally advanced rectal cancer: A phase II study.
First Author: Janice Zhao
Poster
2021 Gastrointestinal Cancers Symposium
Olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab: Phase III LYNK-003 study.
First Author: Carlos Alberto Mayo